BridgeBio Pharma (BBIO) Stock Forecast & Price Target

Compare

1,353 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBIO Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

BridgeBio

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$63.25

▲(35.32%Upside)

Based on 18 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $63.25 with a high forecast of $95.00 and a low forecast of $42.00. The average price target represents a 35.32% change from the last price of $46.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","96":"$96","41.25":"$41.3","59.5":"$59.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.25,59.5,77.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,46.79692307692308,50.81384615384616,54.830769230769235,58.84769230769231,62.86461538461539,66.88153846153847,70.89846153846153,74.91538461538462,78.93230769230769,82.94923076923078,86.96615384615384,90.98307692307692,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,44.354615384615386,45.92923076923077,47.503846153846155,49.07846153846154,50.653076923076924,52.22769230769231,53.80230769230769,55.37692307692308,56.95153846153846,58.526153846153846,60.10076923076923,61.675384615384615,{"y":63.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,42.72,42.660000000000004,42.6,42.54,42.480000000000004,42.42,42.36,42.3,42.24,42.18,42.12,42.06,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$63.25

Lowest Price Target$42.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$44

Hold

-5.86%

Downside

Reiterated

06/24/25

BridgeBio Pharma benefits from strong technical momentum and positive earnings call with successful product launches and pipeline progress. However, financial performance and valuation concerns due to unprofitability and high leverage weigh heavily on the overall score.

Mani ForooharLeerink Partners

Leerink Partners

$53→$56

Buy

19.81%

Upside

Reiterated

07/15/25

BridgeBio Pharma's Promising Diversification and High-Margin Opportunities Drive Buy Rating

David LebowitzCiti

Citi

$58→$67

Buy

43.35%

Upside

Reiterated

07/14/25

BridgeBio Pharma's Promising Prospects: Buy Rating Driven by BBP-418's Potential in Rare Neuromuscular Disorder

Andrew TsaiJefferies

Jefferies

$70

Buy

49.76%

Upside

Initiated

07/14/25

BridgeBio Pharma (BBIO) Receives a Buy from Jefferies

Greg HarrisonScotiabank

Scotiabank

$55

Buy

17.67%

Upside

Reiterated

07/14/25

Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Biren AminPiper Sandler

Piper Sandler

$63→$68

Buy

45.49%

Upside

Reiterated

07/14/25

BridgeBio price target raised to $68 from $63 at Piper SandlerBridgeBio price target raised to $68 from $63 at Piper Sandler

Jason ZemanskyBank of America Securities

Bank of America Securities

$54

Buy

15.53%

Upside

Reiterated

07/11/25

BridgeBio Pharma's Growth Potential Highlighted by Positive Outlook on BBP-418 and FDA Support

Tiago FauthWells Fargo

Wells Fargo

$76

Buy

62.60%

Upside

Reiterated

07/11/25

BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy

Kostas BiliourisBMO Capital

BMO Capital

$42

Hold

-10.14%

Downside

Reiterated

07/11/25

Cautious Hold Rating for BridgeBio Pharma Amid Attruby Sales Focus and BBP-418 Regulatory Prospects

Trevor AllredOppenheimer

Oppenheimer

$60

Buy

28.37%

Upside

Upgraded

07/09/25

BridgeBio upgraded to Outperform from Perform at OppenheimerBridgeBio upgraded to Outperform from Perform at Oppenheimer

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$95

Buy

103.25%

Upside

Reiterated

07/03/25

Cantor Fitzgerald Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Danielle BrillRaymond James

Raymond James

$57

Buy

21.95%

Upside

Reiterated

06/30/25

Raymond James Remains a Buy on BridgeBio Pharma (BBIO)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/24/25

BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen

Cory KasimovEvercore ISI

Evercore ISI

$70→$75

Buy

60.46%

Upside

Reiterated

06/20/25

Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)

Andy ChenWolfe Research

Wolfe Research

$49

Buy

4.84%

Upside

Initiated

06/16/25

BridgeBio initiated with an Outperform at Wolfe ResearchBridgeBio initiated with an Outperform at Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$44

Hold

-5.86%

Downside

Reiterated

06/24/25

Mani ForooharLeerink Partners

Leerink Partners

$53→$56

Buy

19.81%

Upside

Reiterated

07/15/25

BridgeBio Pharma's Promising Diversification and High-Margin Opportunities Drive Buy Rating

David LebowitzCiti

Citi

$58→$67

Buy

43.35%

Upside

Reiterated

07/14/25

BridgeBio Pharma's Promising Prospects: Buy Rating Driven by BBP-418's Potential in Rare Neuromuscular Disorder

Andrew TsaiJefferies

Jefferies

$70

Buy

49.76%

Upside

Initiated

07/14/25

BridgeBio Pharma (BBIO) Receives a Buy from Jefferies

Greg HarrisonScotiabank

Scotiabank

$55

Buy

17.67%

Upside

Reiterated

07/14/25

Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Biren AminPiper Sandler

Piper Sandler

$63→$68

Buy

45.49%

Upside

Reiterated

07/14/25

BridgeBio price target raised to $68 from $63 at Piper SandlerBridgeBio price target raised to $68 from $63 at Piper Sandler

Jason ZemanskyBank of America Securities

Bank of America Securities

$54

Buy

15.53%

Upside

Reiterated

07/11/25

BridgeBio Pharma's Growth Potential Highlighted by Positive Outlook on BBP-418 and FDA Support

Tiago FauthWells Fargo

Wells Fargo

$76

Buy

62.60%

Upside

Reiterated

07/11/25

BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy

Kostas BiliourisBMO Capital

BMO Capital

$42

Hold

-10.14%

Downside

Reiterated

07/11/25

Cautious Hold Rating for BridgeBio Pharma Amid Attruby Sales Focus and BBP-418 Regulatory Prospects

Trevor AllredOppenheimer

Oppenheimer

$60

Buy

28.37%

Upside

Upgraded

07/09/25

BridgeBio upgraded to Outperform from Perform at OppenheimerBridgeBio upgraded to Outperform from Perform at Oppenheimer

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$95

Buy

103.25%

Upside

Reiterated

07/03/25

Cantor Fitzgerald Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Danielle BrillRaymond James

Raymond James

$57

Buy

21.95%

Upside

Reiterated

06/30/25

Raymond James Remains a Buy on BridgeBio Pharma (BBIO)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/24/25

BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen

Cory KasimovEvercore ISI

Evercore ISI

$70→$75

Buy

60.46%

Upside

Reiterated

06/20/25

Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)

Andy ChenWolfe Research

Wolfe Research

$49

Buy

4.84%

Upside

Initiated

06/16/25

BridgeBio initiated with an Outperform at Wolfe ResearchBridgeBio initiated with an Outperform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

+12.77%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +12.77% per trade.

3 Months

xxx

Success Rate

12/15 ratings generated profit

Average Return

+27.66%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +27.66% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

18/20 ratings generated profit

Average Return

+38.64%

reiterated a buy rating 26 days ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +38.64% per trade.

2 Years

xxx

Success Rate

20/21 ratings generated profit

Average Return

+94.95%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +94.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBIO has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 63.25.

Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.75 with a range of -$1.10 to -$0.34. The previous quarter’s EPS was -$0.88. BBIO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year BBIO has Preformed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $99.72M with a range of $54.73M to $182.40M. The previous quarter’s sales results were $116.63M. BBIO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year BBIO has Preformed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 63.25.

What is BBIO’s upside potential, based on the analysts’ average price target?

BridgeBio Pharma Inc has 35.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBIO a Buy, Sell or Hold?

BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is BridgeBio Pharma Inc’s price target?

The average price target for BridgeBio Pharma Inc is 63.25. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $42.00. The average price target represents 35.32% Increase from the current price of $46.74.

What do analysts say about BridgeBio Pharma Inc?

BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of BBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BBIO Analyst Ratings

BBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Pharma

BBIO Analyst Recommendation Trends

BBIO Financial Forecast

BBIO Earnings Forecast

BBIO Sales Forecast

BBIO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts